IRIR: High Resolution Imaging of Retinal Vessels as a Biomarker of Cardiovascular Disease in Patients With Renal Insufficiency - RI

Sponsor
Ramsay Générale de Santé (Other)
Overall Status
Unknown status
CT.gov ID
NCT04116814
Collaborator
Dr Céline FAURE (Other)
83
1
47.3
1.8

Study Details

Study Description

Brief Summary

The objectives are to better understand, in the dialysis patient, the relationships between microvascular morphometry and cardiovascular events, survival, arterial hypertension, the pathology responsible for renal failure, the age of dialysis and metabolic parameters.

The investigator team also want to better understand the relationship between the diameter of small arteries and parameters such as hypertension, the pathology that causes kidney failure, the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes, BNP, lipid balance, phosphocalcic balance).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: wall-to-lumen ratio measurement

Detailed Description

The cardiovascular morbidity of a dialysis patient is 10 times higher than that of a subject in the general population. The patient with renal insufficiency is therefore at high cardiovascular risk. An increase in the wall-to-lumen ratio (WLR) is an early sign of microvascular damage, predictive of the risk of a cardiovascular event. The benefits of WLR measurement are therefore at the level of both the diagnosis and prognosis of vascular disease. Recently, a fundus camera coupled with an adaptive optics system has been able to measure for the first time in vivo non-invasively and reproducibly the wall thickness of the small arteries of the retina, and therefore the WLR, among other biomarkers relating to microvascular remodelling.

Studies in hypertension have confirmed that the rtX1 camera allows reliable and reproducible measurements of the WLR. The main aim of our study is to evaluate the value of the WLR as a biomarker of the risk of cardiovascular morbidity and mortality in patients with renal insufficiency.

The objectives are to better understand, in the dialysis patient, the relationships between microvascular morphometry and cardiovascular events, survival, arterial hypertension, the pathology responsible for renal failure, the age of dialysis and metabolic parameters.

The investigator team also want to better understand the relationship between the diameter of small arteries and parameters such as hypertension, the pathology that causes kidney failure, the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes, BNP, lipid balance, phosphocalcic balance).

Study Design

Study Type:
Observational
Actual Enrollment :
83 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
High Resolution Imaging of Retinal Vessels as a Biomarker of Cardiovascular Disease in Patients With Renal Insufficiency - (IRIR)
Actual Study Start Date :
Apr 21, 2018
Anticipated Primary Completion Date :
Mar 29, 2022
Anticipated Study Completion Date :
Mar 31, 2022

Outcome Measures

Primary Outcome Measures

  1. Predictibilty of WLR [3 years]

    The primary endpoint is time to event (cardiovascular events or death) in months, assessed by survival analysis.

Secondary Outcome Measures

  1. WLR associated biomarker [3 years]

    Secondary endpoints: - Association between WLR and cardiovascular risk factors, medical history and metabolic parameters.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Adult

  • Patients with renal insufficiency: waiting for management (dialysis or transplant), during dialysis or after a kidney transplant followed in the nephrology department of the Saint Martin clinic.

  • First examination in adaptive optics giving a usable result (possibility of measuring the WLR)

  • Affiliate or beneficiary of a social security scheme

  • Patient having given their free and informed consent

Exclusion Criteria:
  • Protected patients: adults under guardianship, trusteeship or other legal protection, deprived of liberty by judicial or administrative decision, hospitalised without consent.

  • Pregnant, lactating or parturient women.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Saint Martin Private Hospital Caen Normandy France 14050

Sponsors and Collaborators

  • Ramsay Générale de Santé
  • Dr Céline FAURE

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ramsay Générale de Santé
ClinicalTrials.gov Identifier:
NCT04116814
Other Study ID Numbers:
  • 2017-A03143-50
First Posted:
Oct 7, 2019
Last Update Posted:
Oct 10, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2019